my A1c moved and I cannot work out whether phase 2 is why
Long-ish post, sorry. tl;dr at the bottom. I have been tracking retatrutide against eGFR for 31 weeks because I could not find anyone who had. The correlation is weaker than I expected, which is itself mildly interesting given how confidently people link the two in here. Caveats up front: one person, one lab, one…
I love that this community will spend 40 comments on a detail. That pedantry is why the numbers here matter.
Strongly agree. Heart rate escalation needs the actual data, not impressions.
phase 2 numbers are not maintenance numbers, cite the trial
[removed by moderator]
triple agonism is phase 2, do not generalise
the glucagon component changes the side effect profile, not just the efficacy
the dosing is steep, the nausea reports are real, and nobody knows the human safety yet
the glucagon component changes the side effect profile, not just the efficacy
Strongly agree. Heart rate escalation needs the actual data, not impressions.
heart rate and dose escalation need actual measurements, not impressions
the glucagon component changes the side effect profile, not just the efficacy
Yes, exactly this, and it is the bit that took me 52 weeks to accept.
the weight curves are unusually steep, which makes predicting individual response harder
You have restated the marketing copy. What is the actual substance here.